Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 and oxaliplatin chemotherapy with or without DC+CIK immunotherapy in gastric cancer
ChiCTR-IPR-15005923Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of tegafur, oxaliplatin and TriMix-DC in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Progression-free survival, Overall survival and 1 more. Started Feb 2015; status: recruiting.
02
Drugs
tegafuroxaliplatinTriMix-DC
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-IPR-15005923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005923.